Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nano Labs (NA) Non-Current Deffered Revenue (2022 - 2025)

Nano Labs' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $9.8 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $9.8 million for Q4 2025, down 29.02% from a year ago — trailing twelve months through Dec 2025 was $9.8 million (down 29.02% YoY), and the annual figure for FY2025 was $9.9 million, down 28.32%.
  • Non-Current Deffered Revenue for Q4 2025 was $9.8 million at Nano Labs, down from $13.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $17.5 million in Q4 2022 to a low of $9.8 million in Q4 2025.
  • The 4-year median for Non-Current Deffered Revenue is $14.4 million (2023), against an average of $14.0 million.
  • The sharpest move saw Non-Current Deffered Revenue decreased 8.07% in 2024, then decreased 29.02% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $17.5 million in 2022, then decreased by 14.43% to $15.0 million in 2023, then decreased by 8.07% to $13.8 million in 2024, then decreased by 29.02% to $9.8 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $9.8 million, $13.8 million, and $15.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.